Source - RNS
RNS Number : 3364K
Oxford Biomedica PLC
09 April 2018
 

 

 

 

 

 

 

Director Dealings / Market Share Purchase

 

Oxford, UK - 09 April 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Andrew Heath, Deputy Chairman and Senior Independent Director has purchased 192,914 ordinary shares of 1p each ("Ordinary Shares") in the Company on 09 April 2018 on the London Stock Exchange at a price of 10.9p per share. Following this purchase Dr. Andrew Heath holds 1,800,000 ordinary shares representing 0.06% of the Company.

 

120,720 Ordinary Shares were purchased by Dr. Heath's wife (Eva Lackner) and are therefore considered a beneficial holding of Dr. Heath. The balance was purchased in his own name.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 

 

 1.

Details of the person discharging material responsibilities/person closely                 associated

 

 a.

Name

 Dr. Andrew Heath

 

 2.

Reason for the notification

 

 a.

Position/status

 Deputy Chairman and Senior Independent Director

 

 b.

Initial notification /amendment

 Initial notification

 

3.

Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor

 

 a.

Name

 Oxford BioMedica plc

 

 b.

Legal Entity Identifier

 213800S1GVQNXQ15K851

 

4.

Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 a.

Description of the financial instrument, type of instrument identification code

 Oxford BioMedica plc Ordinary Shares of 1p each

 

 

 GB0006648157

 

b.

Nature of the transaction

 Purchase of ordinary shares

 

c.

Currency

 GBP - British Pound

 

d.

Price(s) and volume(s)

 

Price(s)

 

 

Volume(s)

 

 

£0.11

72,194

e.

Aggregated information

·      Aggregated volume

·      Price

·      Aggregated total

 

 

 72,194

 

 £0.109

 £7,834.20

 

f.

Date of the transaction

 2018-04-09

 

g.

Place of the transaction

 London Stock Exchange, Main Market (XLON)

 

 

 1.

Details of the person discharging material responsibilities/person closely                 associated

 

 a.

Name

 Eva Lackner

 

 2.

Reason for the notification

 

 a.

Position/status

 Person closely associated with Dr. Andrew Heath, Deputy Chairman and Senior Independent Director

 

 b.

Initial notification /amendment

 Initial notification

 

3.

Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor

 

 a.

Name

 Oxford BioMedica plc

 

 b.

Legal Entity Identifier

 213800S1GVQNXQ15K851

 

4.

Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 a.

Description of the financial instrument, type of instrument identification code

 Oxford BioMedica plc Ordinary Shares of 1p each

 

 

 GB0006648157

 

b.

Nature of the transaction

 Purchase of ordinary shares

 

c.

Currency

 GBP - British Pound

 

d.

Price(s) and volume(s)

 

Price(s)

 

 

Volume(s)

£0.11

720

£0.11

120,000

e.

Aggregated information

·      Aggregated volume

·      Price

·      Aggregated total

 

 

 120,720

 

 £0.109

 £13,101.48

 

f.

Date of the transaction

 2018-04-09

 

g.

Place of the transaction

 London Stock Exchange, Main Market (XLON)

 

 

 

The issued share capital of the Group is 3,283,790,680 ordinary 1p shares.                   

 

 

 

-Ends-

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson,  Chief Executive Officer

Stuart Paynter, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Financial and corporate communications enquiries:

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

 

Notes for editors

 

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBLGDSIXGBGIC